NASDAQ:VRTX Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis $497.61 -5.89 (-1.17%) As of 10:31 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vertex Pharmaceuticals Stock (NASDAQ:VRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vertex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$497.44▼$507.4150-Day Range$470.72▼$557.9652-Week Range$400.86▼$560.25Volume66,856 shsAverage Volume1.37 million shsMarket Capitalization$126.30 billionP/E Ratio28.96Dividend YieldN/APrice Target$575.13Consensus RatingModerate Buy Company Overview Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in molecular biology, genetics and drug discovery to address conditions with significant unmet medical needs. Vertex is best known for its portfolio of cystic fibrosis treatments, including Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis by addressing defects in the CFTR protein. The company serves patients and healthcare providers in the United States and international markets through regulatory approvals and commercial operations across multiple regions. Vertex also commercializes Casgevy, a gene-editing therapy developed with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia. In addition, the company markets Journavx, a non-opioid treatment for acute pain, and is advancing research programs in areas including type 1 diabetes, kidney disease and other serious conditions. Reshma Kewalramani has served as Vertex’s president and chief executive officer since 2017.AI Generated. May Contain Errors. Read More Vertex Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreVRTX MarketRank™: Vertex Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 113th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingVertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 20 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialVertex Pharmaceuticals has a consensus price target of $575.13, representing about 13.8% upside from its current price of $505.39.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vertex Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.01% Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 10.01% in the coming year, from $16.68 to $18.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is 29.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is 29.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.34.Price to Earnings Growth RatioVertex Pharmaceuticals has a PEG Ratio of 2.21. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vertex Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.86% of the float of Vertex Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVertex Pharmaceuticals has a short interest ratio ("days to cover") of 5.03.Change versus previous monthShort interest in Vertex Pharmaceuticals has recently increased by 1.23%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.78 News SentimentVertex Pharmaceuticals has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Vertex Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest37 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows30 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 15% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.20% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vertex Pharmaceuticals' insider trading history. Receive VRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRTX Stock News HeadlinesVertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowOctober 5 at 9:16 AM | finance.yahoo.comAmgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?October 4 at 10:14 AM | fool.comWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure investment in Finland. Cerebras followed with plans for a 165 MW data center worth up to 1.7 billion euros. One small Nasdaq-listed company built its Nordic footprint before this wave hit, with up to 190 MW of capacity approaching ready-for-service status in 2027 to early 2028. Recent long-term data center deals have valued capacity at 1.7 to 2 million dollars per MW annually. See why this overlooked company could be next in the AI infrastructure spotlight.October 6 at 1:00 AM | The Tomorrow Investor (Ad)Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Crosses Above 200 Day Moving Average - Here's WhyOctober 3 at 2:01 AM | americanbankingnews.comVertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different BetsOctober 2, 2026 | finance.yahoo.comCRISPR Therapeutics to Present Phase 1 Data on Zugo-cel in Refractory Systemic Sclerosis at ACR Convergence 2026October 2, 2026 | quiverquant.comQVertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to KnowOctober 1, 2026 | finance.yahoo.comVertex Pharmaceuticals And 2 Other Top Gene Therapy StocksOctober 1, 2026 | finance.yahoo.comSee More Headlines VRTX Stock Analysis - Frequently Asked Questions How have VRTX shares performed this year? Vertex Pharmaceuticals' stock was trading at $453.36 at the beginning of the year. Since then, VRTX stock has increased by 11.5% and is now trading at $505.3880. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Monday, August, 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts' consensus estimates of $4.74 by $0.01. Vertex Pharmaceuticals's revenue for the quarter was up 12.5% on a year-over-year basis. Read the conference call transcript. Does Vertex Pharmaceuticals have any subsidiaries? Vertex Pharmaceuticals subsidiaries include these companies: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others. Who are Vertex Pharmaceuticals' major shareholders? Vertex Pharmaceuticals' top institutional investors include Central Pacific Bank Trust Division and Coastline Trust Co. Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, David Altshuler, Joy Liu, Edward Morrow Atkinson III, Carmen Bozic, Jonathan Biller, Duncan Mckechnie, Mark E Bunnage, Kristen Ambrose and Sangeeta N Bhatia. View institutional ownership trends. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), Qualcomm (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings8/03/2026Today10/06/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VRTX's financial health is in the Green zone, according to TradeSmith. VRTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VRTX CIK875320 Webwww.vrtx.com Phone(617) 341-6100Fax617-576-2109Employees6,400Year Founded1989Price Target and Rating Average Price Target for Vertex Pharmaceuticals$575.13 High Price Target$665.00 Low Price Target$442.00 Potential Upside/Downside+15.4%Consensus RatingModerate Buy Rating Score (0-4)2.96 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)$17.18 Trailing P/E Ratio28.99 Forward P/E Ratio29.87 P/E Growth2.21Net Income$3.95 billion Net Margins35.00% Pretax Margin41.90% Return on Equity23.09% Return on Assets16.72% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio2.74 Sales & Book Value Annual Sales$12.59 billion Price / Sales10.05 Cash Flow$17.35 per share Price / Cash Flow28.72 Book Value$73.57 per share Price / Book6.77Miscellaneous Outstanding Shares253,805,000Free Float253,297,000Market Cap$126.47 billion OptionableOptionable Beta0.28 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:VRTX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...Priority Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
